Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | SCN10A | Q9Y5Y9 | 6/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.33 |
| ▸ | VNN1 | O95497 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13386460 | 0.81 | HDAC6 (0.38) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL13386453 | 0.77 | HDAC6 (0.35) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL1871882 | 0.75 | CCR1 (0.46) | CCR1ADRB1KCNH2SCN10AVNN1 | |
| SCHEMBL2432018 | 0.74 | HDAC3 (0.31) | HDAC3HDAC1HDAC2HDAC6VNN1 | |
| Trifluoroacetic Acid SCHEMBL1670534 | 0.73 | CCR1 (0.38) | CCR1ADRB1KCNH2SCN10A | |
| SCHEMBL12002508 | 0.69 | LMNA (0.45) | CCR1ADRB1KCNH2SCN10ASYK | |
| SCHEMBL1672692 | 0.68 | LMNA (0.40) | CCR1ADRB1KCNH2SCN10ASYK | |
| SCHEMBL13386499 | 0.67 | AKT1 (0.40) | CCR1ADRB1KCNH2 | |
| SCHEMBL12669495 | 0.67 | CCR1 (0.36) | CCR1ADRB1KCNH2VNN1 | |
| SCHEMBL2986859 | 0.66 | VNN1 (0.39) | VNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9056858-B2 | Indazole and pyrazolopyridine compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-16 | — | — | US | disclosed |
| EP-2491028-B1 | INDAZOLE AND PYRAZOLOPYRIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2013-12-11 | — | — | EP | disclosed |
| US-20120270870-A1 | Indazole and Pyrazolopyridine Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| CN-102666526-A | Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists | BOEHRINGER INGELHEIM INT | 2012-09-12 | — | — | CN | disclosed |
| EP-2491028-A1 | INDAZOLE AND PYRAZOLOPYRIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011049917-A1 | INDAZOLE AND PYRAZOLOPYRIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270870-A1 | Indazole and Pyrazolopyridine Compounds As CCR1 Receptor Antagonists | CCR1, CCRL2, CCR3 | CCR1 1/4885ADRB1 31/4885KCNH2 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.